Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 418

1.

Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.

Butt DA, Mamdani M, Gomes T, Lix L, Lu H, Tu K; Hypertension Outcome, Surveillance Team.

J Bone Miner Res. 2014 Nov;29(11):2483-8. doi: 10.1002/jbmr.2271.

2.

Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.

Kunutsor SK, Blom AW, Whitehouse MR, Kehoe PG, Laukkanen JA.

Eur J Epidemiol. 2017 Nov;32(11):947-959. doi: 10.1007/s10654-017-0285-4. Epub 2017 Jul 27.

3.

Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.

Hsiao FC, Tung YC, Chou SH, Wu LS, Lin CP, Wang CL, Lin YS, Chang CJ, Chu PH.

Medicine (Baltimore). 2015 Dec;94(51):e2355. doi: 10.1097/MD.0000000000002355.

4.

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.

Roy J, Shah NR, Wood GC, Townsend R, Hennessy S.

J Clin Hypertens (Greenwich). 2012 Jul;14(7):407-14. doi: 10.1111/j.1751-7176.2012.00617.x. Epub 2012 Apr 9.

5.
7.
8.

Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and risk of appendicitis.

Mukamal KJ, Ghimire S, Pandey R, Fiarman GS, Gautam S.

Ann Epidemiol. 2012 Oct;22(10):747-50. doi: 10.1016/j.annepidem.2012.07.001. Epub 2012 Aug 4.

PMID:
22867943
9.

Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.

Shih CJ, Chen HT, Kuo SC, Li SY, Lai PH, Chen SC, Ou SM, Chen YT.

CMAJ. 2016 May 17;188(8):E148-57. doi: 10.1503/cmaj.150771. Epub 2016 Mar 21.

10.

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.

Kuan YC, Huang KW, Yen DJ, Hu CJ, Lin CL, Kao CH.

Int J Cardiol. 2016 Oct 1;220:462-6. doi: 10.1016/j.ijcard.2016.06.215. Epub 2016 Jun 27.

PMID:
27390970
11.
12.

The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study.

Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, Lee HH, Chung W, Jung JY.

Am J Kidney Dis. 2012 Oct;60(4):576-82. doi: 10.1053/j.ajkd.2012.04.017. Epub 2012 May 31. Erratum in: Am J Kidney Dis. 2013 May;61(5):849.

PMID:
22658321
13.

Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.

Walker AM, Liang C, Clifford CR, Parker C, Feldman A.

Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):348-56. doi: 10.1002/pds.3558. Epub 2013 Dec 23.

PMID:
24375940
14.

A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age ≥ 65 years.

Zhang Y, Fonarow GC, Sanders PW, Farahmand F, Allman RM, Aban IB, Love TE, Levesque R, Kilgore ML, Ahmed A.

Am J Cardiol. 2011 Nov 15;108(10):1443-8. doi: 10.1016/j.amjcard.2011.06.066. Epub 2011 Sep 3.

15.

Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users.

de Jong HJ, Vandebriel RJ, Saldi SR, van Dijk L, van Loveren H, Cohen Tervaert JW, Klungel OH.

Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):835-43. doi: 10.1002/pds.3291. Epub 2012 Jun 6.

PMID:
22674737
16.

Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.

Sørensen GV, Ganz PA, Cole SW, Pedersen LA, Sørensen HT, Cronin-Fenton DP, Garne JP, Christiansen PM, Lash TL, Ahern TP.

J Clin Oncol. 2013 Jun 20;31(18):2265-72. doi: 10.1200/JCO.2012.43.9190. Epub 2013 May 6.

17.

Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis.

Caldeira D, David C, Sampaio C.

Am J Cardiovasc Drugs. 2012 Aug 1;12(4):263-77. doi: 10.2165/11599990-000000000-00000. Review.

PMID:
22587776
18.

Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.

Shih CJ, Chen HT, Chao PW, Kuo SC, Li SY, Yang CY, Tarng DC, Ou SM, Chen YT.

J Hypertens. 2016 Mar;34(3):567-74; discussion 575. doi: 10.1097/HJH.0000000000000804.

PMID:
26703918
19.

Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study.

Chiang YY, Chen KB, Tsai TH, Tsai WC.

J Clin Hypertens (Greenwich). 2014 Jan;16(1):27-33. doi: 10.1111/jch.12228. Epub 2013 Nov 8.

20.

Risk of hospitalization for community acquired pneumonia with renin-angiotensin blockade in elderly patients: a population-based study.

Shah S, McArthur E, Farag A, Nartey M, Fleet JL, Knoll GA, Kim SJ, Garg AX, Jain AK.

PLoS One. 2014 Oct 29;9(10):e110165. doi: 10.1371/journal.pone.0110165. eCollection 2014.

Supplemental Content

Support Center